<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CYPROHEPTADINE HYDROCHLORIDE</span><br/>(si-proe-hep'ta-deen)<br/><span class="topboxtradename">Periactin, </span><span class="topboxtradename">Vimicon <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">antihistamine, h<sub>1</sub>-receptor antagonist</span>; <span class="classification">antipruritic</span><br/><b>Prototype: </b>Diphenhydramine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>4 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Potent piperidine antihistamine with pharmacologic actions similar to those of azatadine. Acts by competing with histamine
         for H<sub>1</sub>-receptor sites on effector cells, thus preventing histamine-mediated responses.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces mild central depression and moderate anticholinergic effects; lacks antiemetic action. Has significant antipruritic,
         local anesthetic, and antiserotonin activity.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic relief of various allergic conditions, including hay fever, vasomotor rhinitis, allergic conjunctivitis, urticaria
         caused by cold sensitivity, and pruritus of allergic dermatoses. Effective in treatment of anaphylactoid reactions as adjunct
         to epinephrine and other standard measures after acute symptoms have been controlled.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Cushing's disease, carcinoid syndrome, vascular headaches, appetite stimulant.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cyproheptadine or other H<sub>1</sub>-receptor antagonist antihistamines; acute asthma attack. Safe use during pregnancy (category B), lactation, and in children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Older adult and debilitated patients; patients predisposed to urinary retention; glaucoma; asthma; hyperthyroidism; cardiovascular
         disease, hypertension; GI or GU tract obstruction.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergies</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 4 mg t.i.d. or q.i.d. (420 mg/d), max 0.5 mg/kg/d<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 4 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.25 mg/kg/d in 34 divided doses (max: 12 mg/d for <i>26 y</i>, 16 mg/d for <i>612 y</i>)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>GI adverse effects may be minimized by administering drug with food or milk.</li>
<li>Store in tightly covered container at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span>
<span class="speceff-common">Dry mouth,</span> nausea, vomiting, epigastric distress, appetite stimulation, weight gain, transient decrease in fasting blood sugar level,
      increased serum amylase level, cholestatic jaundice. <span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> dizziness, faintness, headache, tremulousness, fatigue, disturbed coordination. <span class="typehead">Respiratory:</span> Thickened bronchial secretions. <span class="typehead">Skin:</span> Skin rash. <span class="typehead">Special Senses:</span> Dry nose and throat. <span class="typehead">Urogenital:</span> Urinary frequency, retention, and difficult urination. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>As a general rule, antihistamines are discontinued about 4 d before <span class="alt">skin testing procedures</span> are to be performed because they may produce false-negative results.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and <span class="classification">cns depressants</span> add to CNS depression; <span class="classification">tricyclic antidepressants</span> and other <span class="classification">anticholinergics</span> have additive anticholinergic effects; may inhibit pressor effects of <b>epinephrine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Duration:</span> 69 h. <span class="typehead">Distribution:</span> Distribution into breast milk not known. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor level of alertness. In some patients, the sedative effect disappears spontaneously after 34 d of drug administration.</li>
<li>Since drug may cause dizziness, supervision of ambulation and other safety precautions may be warranted.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid activities requiring mental alertness and physical coordination, such as driving a car, until reaction to the drug is
            known.
         </li>
<li>Drug causes sedation, dizziness, and hypotension in older adults. Report these symptoms. Children are more apt to manifest
            CNS stimulation, e.g., confusion, agitation, tremors, hallucinations. Reduction in dosage may be indicated.
         </li>
<li>Cyproheptadine may increase and prolong the effects of alcohol, barbiturates, narcotic analgesics, anxiolytics, and other
            CNS depressants.
         </li>
<li>Monitor weight and keep physician informed of any significant weight gain.</li>
<li>Maintain sufficient fluid intake to help to relieve dry mouth and also reduce risk of cholestatic jaundice.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>